Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease
Open Access
- 1 January 2000
- journal article
- research article
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 38 (1) , 29-40
Abstract
Three forms of feline immunodeficiency virus protease (FIV PR), the wild type (wt) and two single point mutants, V59I and Q99V, as well as human immunodeficiency virus type 1 protease (HIV‐1 PR), were cocrystallized with the C2‐symmetric inhibitor, TL‐3. The mutants of FIV PR were designed to replace residues involved in enzyme‐ligand interactions by the corresponding HIV‐1 PR residues at the structurally equivalent position. TL‐3 shows decreased (improved) inhibition constants with these FIV PR mutants relative to wt FIV PR. Despite similar modes of binding of the inhibitor to all PRs (from P3 to P3′), small differences are evident in the conformation of the Phe side chains of TL‐3 at the P1 and P1′ positions in the complexes with the mutated FIV PRs. The differences mimick the observed binding of TL‐3 in HIV‐1 PR and correlate with a significant improvement in the inhibition constants of TL‐3 with the two mutant FIV PRs. Large differences between the HIV‐1 and FIV PR complexes are evident in the binding modes of the carboxybenzyl groups of TL‐3 at P4 and P4′. In HIV‐1 PR:TL‐3, these groups bind over the flap region, whereas in the FIV PR complexes, the rings are located along the major axis of the active site. A significant difference in the location of the flaps in this region of the HIV‐1 and FIV PRs correlates with the observed conformational changes in the binding mode of the peptidomimetic inhibitor at the P4 and P4′ positions. These findings provide a structural explanation of the observed Ki values for TL‐3 with the different PRs and will further assist in the development of improved inhibitors. Proteins 2000;38:29–40. Published 2000 Wiley‐Liss, Inc.Keywords
This publication has 34 references indexed in Scilit:
- Workshop Summary : Lessons from the Cat: Feline Immunodeficiency Virus as a Tool to Develop Intervention Strategies against Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1998
- Anti-Human Immunodeficiency Virus Drug Combination StrategiesAntiviral Chemistry and Chemotherapy, 1998
- INHIBITORS OF HIV-1 PROTEASE: A Major Success of Structure-Assisted Drug DesignAnnual Review of Biophysics, 1998
- Automated Docking and the Search for HIV Protease InhibitorsSAR and QSAR in Environmental Research, 1998
- Animal Models of HIV-1 DiseaseScience, 1997
- FIV infection of the domestic cat: an animal model for AIDSImmunology Today, 1997
- Feline immunodeficiency virus infection--a model for HIV and AIDS?Journal of Medical Microbiology, 1995
- Feline Immunodeficiency Virus as a Model For Development of Molecular Approaches to Intervention Strategies Against Lentivirus Infections1995
- Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogenClinical Microbiology Reviews, 1995
- Isolation of a T-Lymphotropic Virus from Domestic Cats with an Immunodeficiency-Like SyndromeScience, 1987